Journal Mobile Options
Table of Contents
Vol. 84, No. 4, 2013
Issue release date: March 2013
Section title: Clinical Study
Oncology 2013;84:233–239
(DOI:10.1159/000346690)

Phase II Trial of Alternating mFOLFOX6 and FOLFIRI Regimens in the First-Line Treatment for Unresectable or Metastatic Colorectal Cancer (KSCC0701)

Oki E.b · Emi Y.b · Akagi Y.a · Tokunaga S.c · Sadanaga N.d · Tanaka T.e · Ogata Y.a · Saeki H.b · Kakeji Y.f · Baba H.g · Nishimaki T.h · Natsugoe S.i · Shirouzu K.a · Maehara Y.b · Kyushu Study Group of Clinical Cancer
aDepartment of Surgery, Kurume University School of Medicine, Kurume, bDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, cMedical Information Center, Kyushu University Hospital, dDepartment of Surgery, Saiseikai Fukuoka General Hospital, and eDepartment of Surgery, Social Insurance Tagawa Hospital, Fukuoka, fDivision of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, gDepartment of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, hDivision of Digestive and General Surgery, University of the Ryukyus Faculty of Medicine, Okinawa, and iDepartment of Surgical Oncology and Digestive Surgery, Kagoshima University, Kagoshima, Japan

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: 11/1/2012 5:45:54 PM
Accepted: 12/17/2012
Published online: 1/31/2013
Issue release date: March 2013

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 3

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL

Abstract

Objective: This phase II study examined the efficacy and safety of alternating regimens of mFOLFOX6 and FOLFIRI as a first-line treatment for unresectable or metastatic colorectal cancer. Patients and Methods: Forty-eight patients were enrolled in this study. Patients received an alternating regimen of 4 cycles of mFOLFOX6 followed by 4 cycles of FOLFIRI. Results: The characteristics of the study population were as follows: males/females 34/12, median age 66 years (range 43–75) and Eastern Cooperative Oncology Group performance status 0/1/2 in 37/9/0 patients. The overall response rate was 58.7% [95% confidence interval (CI) 43.9–73.5]. The median progression-free survival was 10.3 months (95% CI 7.5–11.9), and the median overall survival was 28.4 months (95% CI 22.5–35.7). Among the 47 patients evaluated for toxicity, the most common grade 3–4 adverse events were leukopenia (26%), neutropenia (55%), anemia (4%), neurotoxicity (0%), diarrhea (2%), febrile neutropenia (4%), nausea (4%), vomiting (2%), and hypersensitivity (0%). Conclusions: The results of this phase II study indicate that this alternating schedule is effective and well tolerated as a first-line treatment for unresectable or metastatic colorectal cancer. The low rate of grade 3 neurotoxicity is also promising.

© 2013 S. Karger AG, Basel


  

Author Contacts

Eiji Oki
Department of Surgery and Science, Graduate School of Medical Sciences
Kyushu University
Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582 (Japan)
E-Mail okieiji@surg2.med.kyushu-u.ac.jp

  

Article Information

Received: November 1, 2012
Accepted after revision: December 17, 2012
Published online: January 31, 2013
Number of Print Pages : 7
Number of Figures : 3, Number of Tables : 3, Number of References : 19

  

Publication Details

Oncology (International Journal for Cancer Research and Treatment)

Vol. 84, No. 4, Year 2013 (Cover Date: March 2013)

Journal Editor: Markman M. (Philadelphia, Pa.)
ISSN: 0030-2414 (Print), eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL


Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: 11/1/2012 5:45:54 PM
Accepted: 12/17/2012
Published online: 1/31/2013
Issue release date: March 2013

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 3

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.